
Oncology NEWS International
- Oncology NEWS International Vol 15 No 9
- Volume 15
- Issue 9
Hana Initiates Marqibo Phase II Trial in Relapsed/Refractory ALL
Hana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.
SOUTH SAN FRANCISCO, CaliforniaHana Biosciences has initiated a multicenter phase II clinical trial of Marqibo (vincristine sulfate liposome injection) in patients with relapsed or refractory acute lymphoblastic leukemia (ALL). The study is designed to support a phase III pivotal clinical trial of Marqibo for ALL, the company said in a press release. The primary objective of the phase II open-label study is to assess the efficacy of weekly doses of Marqibo plus pulse dexamethasone as measured by complete response rate. Hana expects to enroll up to 44 patients.
Articles in this issue
about 19 years ago
Exjade Gains Approval in EUabout 19 years ago
President's Cancer Panel Assesses Progress in Two Areasabout 19 years ago
Cognitive Rx Reduces Depression in Breast Ca Ptsabout 19 years ago
Nurses Develop Evidence-Based Guidelines for Mucositisabout 19 years ago
Anastrozole Therapy for Breast Cancer Affects Bone Healthabout 19 years ago
Is Demand for Trial Subjects Outpacing Supply?about 19 years ago
Postchemo Disappearance of Liver Mets Doesn't Mean Cureabout 19 years ago
Aromasin-Related Bone Loss Affected by Vitamin D LevelsNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































































